Connect Biopharma Holdings Limited Stock Analysis & AI Score
Connect Biopharma Holdings Limited (CNTB) has an ST Score of 31.5 (C-), driven by its Forecast (A+) and held back by its Profitability (F). Analysts rate it Buy with a $6.60 price target (+654.1% upside).
Composite rating from 8 factors. Tap a factor to see the metrics behind its grade.
AI Daily Briefing
Analysis by AICNTB Stock Price History
CNTB Technical Indicators
FMPEarnings Surprises
Analyst Forecast
Revenue Mix
Company Information
| Employees | — |
| CEO | — |
| Sector | Healthcare |
| Industry | Biotechnology |
| IPO Date | — |
| Website | — |
| Country | — |
| Exchange | NASDAQ |
SEC Filings
Annual Report (10-K)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
Quarterly Report (10-Q)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
Analyst Price Target
ESG Score
CNTB Latest Stock News
ST Score
Connect Biopharma Holdings Limited (CNTB) has an ST Score of 31.5 (C-), driven by its Forecast (A+) and held back by its Profitability (F). Analysts rate it Buy with a $6.60 price target (+654.1% upside).
- Strongest
- ForecastA+
- Weakest
- ProfitabilityF
All factor grades
- ForecastA+
- GrowthC+
- Financial StrengthC-
- ValuationD
- MomentumD
- ProfitabilityF
- Piotroski2/9
Press Releases
Company Contact Details
CNTB stock: frequently asked questions
What is CNTB's ST Score?
Connect Biopharma Holdings Limited (CNTB) has an ST Score of 31.5 (C-), on our 0–100 scale where higher is stronger. The ST Score combines eight factor grades — valuation, profitability, financial strength, momentum, growth, forecast, sentiment and Piotroski — into a single A+ to F rating.
Is CNTB a buy, hold, or sell?
Analysts rate CNTB a Buy, with a price target of $6.60 (+654.1% vs the current price). Our ST Score grades it C- (31.5/100). The ST Score is a data-driven signal, not a recommendation.
What are CNTB's factor grades?
Valuation D, Profitability F, Financial Strength C-, Momentum D, Growth C+, Forecast A+.
What is CNTB's valuation grade?
Connect Biopharma Holdings Limited (CNTB) earns a valuation grade of D, measured against Biotechnology peers. The valuation factor looks at multiples such as P/E, P/S, P/B, EV/EBITDA and free cash flow yield.
What is CNTB's growth grade?
Connect Biopharma Holdings Limited (CNTB) earns a growth grade of C+, measured against Biotechnology peers. The growth factor looks at revenue, earnings and cash flow growth over recent quarters and years.
What is CNTB's profitability grade?
Connect Biopharma Holdings Limited (CNTB) earns a profitability grade of F, measured against Biotechnology peers. The profitability factor looks at margins and returns such as gross margin, net margin, ROE and ROIC.
What is CNTB's financial strength grade?
Connect Biopharma Holdings Limited (CNTB) earns a financial strength grade of C-, measured against Biotechnology peers. The financial strength factor looks at debt levels, liquidity and coverage ratios.
What is the analyst price target for CNTB?
The average analyst price target for Connect Biopharma Holdings Limited (CNTB) is $6.60 from 7 analysts, which is +654.1% versus the recent price of $0.88.
What is CNTB's Piotroski score?
Connect Biopharma Holdings Limited (CNTB) has a Piotroski F-Score of 2 out of 9. The Piotroski score checks nine accounting signals covering profitability, leverage and operating efficiency; scores of 8–9 are considered strong and 0–2 weak.